Research Topics
Species | O BaireySummaryAffiliation: Tel Aviv University Country: Israel Publications
| Collaborators
|
Detail Information
Publications
Serum CA 125 as a prognostic factor in non-Hodgkin's lymphomaOsnat Bairey
Institute of Hematology and Felsenstein Medical Research Center, Rabin Medical Center, Beilinson Campus, Petah Tiqva, Israel
Leuk Lymphoma 44:1733-8. 2003..In conclusion, CA 125 is not only a reliable marker for staging and assessing tumor activity in NHL, elevated levels are also predictive of decreased survival...
Early death in patients diagnosed with non-Hodgkin's lymphomaOsnat Bairey
Institute of Hematology, Rabin Medical Center, Petach Tikva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Ann Hematol 92:345-50. 2013....- Insect-bite-like reaction in patients with chronic lymphocytic leukemia: a study from the Israeli Chronic Lymphocytic Leukemia Study GroupOsnat Bairey
Hematology Institute, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel
Eur J Haematol 89:491-6. 2012.... - Presenting features and outcome of chronic lymphocytic leukemia patients diagnosed at age 80 years or more. An ICLLSG studyOsnat Bairey
Institute of Hematology, Rabin Medical Center, Beilinson Hospital, Petah Tiqwa, Israel
Ann Hematol 90:1123-9. 2011..8, 1.6, and 1.9, respectively). Patients diagnosed with CLL at age ≥80 years may expect to live a long life. This study identifies several factors predicting good prognosis which are easy to obtain... - Arsenic-trioxide-induced apoptosis of chronic lymphocytic leukemia cellsO Bairey
Institute of Hematology, Rabin Medical Center, Beilinson Hospital, Petah Tiqwa, Israel
Int J Lab Hematol 32:e77-85. 2010..Further studies are needed to elucidate the potential therapeutic role of As(2)O(3) in CLL... - Is bone marrow biopsy obligatory in all patients with non-Hodgkin's lymphoma?Osnat Bairey
Institute of Hematology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel
Acta Haematol 118:61-4. 2007..We think BMB is not mandatory in every patient with NHL and suggest recommendations for which patients we should continue to perform this procedure on... - Non-Hodgkin's lymphomas of the colonOsnat Bairey
Institute of Hematology, Rabin Medical Center Beilinson Campus, Petah Tiqva, Israel, Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel
Isr Med Assoc J 8:832-5. 2006..Non-Hodgkin's lymphoma of the colon is a rare and consequently poorly studied extranodal lymphoma. Most of the previous publications used old pathologic classifications and old diagnostic and treatment approaches... - Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphomaOsnat Bairey
Institute of Hematology, Rabin Medical Center, Beilinson Campus, Petah Tiqva, Israel
Eur J Haematol 76:384-91. 2006.... - Serum CA 125 levels in patients with chronic lymphocytic leukemiaO Bairey
Institute of Hematology and Felsenstein Medical Research Center, Rabin Medical Center, Beilinson Campus, Petah Tiqva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Clin Lab Haematol 27:57-60. 2005..7%). To conclude, serum CA 125 levels are rarely elevated in CLL patients. It is possible that serum CA 125 levels can help differentiate between equivocal cases of small lymphocytic lymphoma and CLL... - Expression of adhesion molecules on leukemic B cells from chronic lymphocytic leukemia patients with predominantly splenic manifestationsOsnat Bairey
Institute of Hematology, Rabin Medical Center Beilinson Campus, Petah Tiqva, Israel
Isr Med Assoc J 6:147-51. 2004..quot; Among our patients with B cell chronic lymphocytic leukemia 15% demonstrate predominantly splenic manifestations and are classified as stage II(S)... - Clinical severe hepatic venoocclusive disease during induction treatment of acute monoblastic leukemia managed with defibrotideOsnat Bairey
Institute of Hematology, Rabin Medical Center, Beilinson Campus, Petah Tikva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Am J Hematol 69:281-4. 2002..Administration of intravenous defibrotide for 19 days induced complete resolution of the VOD. Further consolidation treatment was resumed including high-dose cytosine arabinoside without further complications... - All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cellsO Bairey
Institute of Hematology and the Felsenstein Medical Research Center, Rabin Medical Center, Beilinson Campus Petah Tikva 49100, Israel
Leuk Res 28:243-8. 2004..These findings suggest that the VEGF transduction pathway may be very active in CLL cells, and both its paracrine and autocrine pathways may contribute to their enhanced survival... - Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemiaO Bairey
Institute of Haematology and the Felsenstein Medical Research Centre, Rabin Medical Centre, Beilinson Campus, Petah Tikva, Israel
Br J Haematol 113:400-6. 2001..These findings indicate that in CLL there is a correlation between angiogenesis-related factors and apoptosis-related protein expression, and elevated bFGF levels may account for the elevated Bcl-2 levels... - Lack of HER-2/neu expression in Hodgkin and non-Hodgkin lymphomaOsnat Bairey
Institutes of Hematology, Rabin Medical Center, Beilinson Campus, Petah Tiqva, Israel
Arch Pathol Lab Med 126:574-6. 2002..The significance of HER-2/neu in lymphomas is unknown. The aim of this study was to evaluate the expression of HER-2/neu in the malignant lymphomas: non-Hodgkin and Hodgkin lymphomas... - Expression of bcl-2 and bax in cells isolated from B-chronic lymphocytic leukemia patients at different stages of the diseaseA Aviram
Division of Haematology, Rabin Medical Center, Petach Tikva, Israel
Eur J Haematol 64:80-4. 2000..058). Of patients in stage C, 45% expressed high levels of both bcl-2 and bax while 50% and 42% of patients at stages A and B had low levels of both proteins... 
Expression of basic fibroblast growth factor is associated with poor outcome in non-Hodgkin's lymphomaI Pazgal
Institute of Hematology and Felsenstein Medical Research Center, Rabin Medical Center, Beilinson Campus, Petah Tiqva, 49100, Israel
Br J Cancer 86:1770-5. 2002....- Microvessel density in chemosensitive and chemoresistant diffuse large B-cell lymphomasO Bairey
Institute of Hematology, and the Felsenstein Medical Research Center, Rabin Medical Center, Petah Tikva, Israel
Med Oncol 17:314-8. 2000..5 (range 11-94). F8RA appears to be more sensitive for staining DLBC lymphomas microvessels than CD-31. Our data demonstrate that there is no correlation between tumor MVD and response to chemotherapy in patients with DLBC lymphomas... - Doxorubicin and a butyric acid derivative effectively reduce levels of BCL-2 protein in the cells of chronic lymphocytic leukemia patientE Rabizadeh
Institute of Hematology and Felsenstein Medical Research Center, Rabin Medical Center, Belinson Campus, Petach Tikva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Eur J Haematol 66:263-71. 2001..These results may be beneficial in possible future combination therapy with AN-9 in B-CLL... - Non-Hodgkin's lymphoma in patients 80 years of age or olderO Bairey
Institute of Hematology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Department of Internal Medicine A, Sapir Medical Center, Kfar Saba, Israel
Ann Oncol 17:928-34. 2006..Very elderly patients (> or =80 years old) with non-Hodgkin's lymphoma (NHL) frequently have co-morbid conditions and are generally excluded from clinical trials or even from treatment. The optimal treatment of these patients is unknown... - Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphomaAdi Broyde
Institute of Hematology, Rabin Medical Center, Beilinson Hospital, Petah Tiqwa, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Am J Hematol 84:338-43. 2009..In diffuse large B-cell lymphoma, a cut-off value of 70% can distinguish patients with a good and bad prognosis when combined with other prognostic factors of low IPI score and bulky disease... - Erythropoietin can obviate the need for repeated heart valve replacement in high-risk patients with severe mechanical hemolytic anemia: case reports and literature reviewY Shapira
The Dan Sheingarten Echocardiography Unit and Valvular Clinic, Department of Cardiology, Rabin Medical Center, Petah Tiqva, Israel
J Heart Valve Dis 10:431-5. 2001..CONCLUSION: EPO may defer or even obviate the need for repeated valve surgery in patients with severe hemolysis due to perivalvular leak, especially those with inadequate EPO response, such as those with renal malfunction... - Salvage chemotherapy with dexamethasone, etoposide, ifosfamide and cisplatin (DVIP) for relapsing and refractory non-Hodgkin's lymphomaAriela Dortort Lazar
Institute of Hematology, Rabin Medical Center Beilinson Campus, Petah Tikva, Israel
Isr Med Assoc J 11:16-22. 2009..There is currently no standard salvage chemotherapy for the 40-50% of patients with non-Hodgkin's lymphoma who fail first-line treatment... - Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphomaChava Perry
Institute of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Eur J Haematol 79:205-9. 2007..In the present study, we evaluated the diagnostic accuracy of PET integrated with CT (PETCT) in patients with MALT lymphoma and assessed its reliability in clinical staging and monitoring response... - Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemiaLev Shvidel
Hematology Institute, Kaplan Medical Center, Rehovot 76100, Israel
Leuk Lymphoma 44:1947-50. 2003.... - Expression of VEGF-C, VEGF-D and their receptor VEGFR-3 in diffuse large B-cell lymphomasIdit Pazgal
Institute of Hematology, Rabin Medical Center, Beilinson Hospital, Petah Tiqwa, Israel
Leuk Lymphoma 48:2213-20. 2007..Our findings indicate the importance of lymphangiogenic factors in the pathogenesis of DLBCL and suggest a potential therapeutic role for antilymphangiogenesis agents... - Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regionsAndres J M Ferreri
Medical Oncology Unit, Department of Oncology, San Raffaele Scientific Institute, Milan, Italy
Haematologica 92:486-92. 2007..This study explored variations in the clinical manifestations of intravascular lymphoma (IVL) on the bases of the association with hemophagocytosis and the country where the diagnosis was made...